Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia

Launched by WECARE PROBIOTICS CO., LTD. · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special type of probiotics on children who have a specific type of lung infection called Mycoplasma pneumoniae pneumonia. The goal is to see if these probiotics can help shorten the time that children are sick compared to a placebo, which is a harmless substance that doesn’t contain any active medicine. The trial is not yet recruiting participants, but it is designed for infants and young children aged 6 months to 3 years who have been diagnosed with this type of pneumonia within the last 48 hours.

To be eligible for the trial, children must meet certain criteria, such as having a confirmed diagnosis of Mycoplasma pneumoniae pneumonia and not having any serious health conditions like heart problems or previous breathing issues. If selected, families can expect to be informed about the study and will need to provide consent for their child to participate. This trial aims to find out if probiotics could be a helpful treatment for this type of pneumonia in young children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meet the diagnostic criteria for pneumonia in "Zhufutang Practical Pediatrics" (7th Edition), and is diagnosed with Mycoplasma pneumoniae pneumonia using tNGS technology;
• • 2. Infants and young children aged 6 months to 3 years;
• • 3. The course of the disease is \<48 h;
• • 4. The family members of the children are informed about the study and sign the informed consent form.
• Exclusion Criteria:
• • 1. Previous history of wheezing;
• • 2. Cardiovascular disease and congenital tracheal dysplasia;
• • 3. pneumonia induced by other causes;
• • 4. Dysplasia of bronchial and pulmonary tracts;
• • 5. premature infants;
• • 6. Combined with immunosuppressive diseases;
• • 7. Presence of mental illness.